scholarly journals ASPN is a Potential Promising Biomarker for Common Heart Failure

2020 ◽  
Author(s):  
Kai Zhang ◽  
Min Wu ◽  
Xianyu Qin ◽  
Xianwu Zhou ◽  
Jianrong Zhou ◽  
...  
Keyword(s):  
Gene Expression ◽  
Heart Failure ◽  
Molecular Mechanisms ◽  
Adult Mortality ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Hub Genes ◽  
Ventricular Ejection Fraction ◽  
Mortality And Morbidity ◽  
Go Annotation

Abstract Background: Heart failure (HF), the leading cause of adult mortality and morbidity worldwide, is the end-stage of various diseases, especially ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM). This study aimed to investigate the common molecular mechanism of ICM and DCM.Methods: Four gene expression datasets, GSE1869, GSE5406, GSE57338, and GSE79962, were obtained from the Gene Expression Omnibus (GEO) database. The differentially expressed genes (DEGs) of ICM or DCM samples compared with those of nonfailing samples were identified. Gene ontology (GO) annotation, Kyoto encyclopedia of gene and genome (KEGG) pathway analysis, and the protein-protein network (PPI) of the coregulated DEGs in at least three datasets were performed using the online tools of DAVID, the KOBAS database, and the STRING database, respectively. Hub genes of HF were analyzed for their correlation with left ventricular ejection fraction (LVEF) in dataset GSE19303. The expression levels of notable DEGs were further validated in our tissue microarray (TMA).Results: Fifty-nine coregulated ICM and sixty-eight coregulated DCM relevant DEGs were identified (in at least three datasets). Moreover, 38 common DEGs between ICM and DCM relevant DEGs were obtained that were mainly involved in inflammatory/stress processes, proliferation, and some lipid metabolism pathways. Among the ten hub genes with top degrees, four genes showed a correlation with LVEF, and ASPN had the most significant correlation. Finally, the expression of ASPN protein was validated in our TMA and was significantly increased in ICM and DCM left ventricular samples.Conclusion: The present study revealed some common molecular mechanisms of HF with different causes. Furthermore, ASPN may be a potential promising biomarker for HF.

scholarly journals Who ′Nose′, is it the ARNi?: A Case Series of Persistent Nasal Pruritus in Heart Failure Patients receiving Sacubitril/Valsartan

2021 ◽  
Author(s):  
Jaclyn Gan ◽  
Haunnah Rheault ◽  
Yee Weng Wong
Keyword(s):  
Heart Failure ◽  
Adverse Effect ◽  
Product Information ◽  
Case Series ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Mortality And Morbidity ◽  
Case Summary

Abstract Background Sacubitril/valsartan is approved for the treatment of chronic heart failure with reduced left ventricular ejection fraction (HFrEF) of less than or equal to 40% to decrease mortality and morbidity. Nasal pruritus is not a recognised adverse effect in the product information. In this case series, we encountered three patients presented with nasal pruritus that improved after discontinuation of sacubitril/valsartan. Case Summary Three patients aged 58-73 years-old presented with pruritus at the nasal septum post-initiation of sacubitril/valsartan. The pruritus did not subside despite the use of anti-histamines. Within 3-6 months, all individuals discontinued sacubitril/valsartan with complete resolution of their nasal pruritus. Discussion Many physicians may not aware of this unusual but reversible adverse effect of sacubitril/valsartan. Despite the positive prognostic value of sacubitril/valsartan, the constant nasal pruritus had impacted the quality of life of our patients, leading them to discontinue sacubitril/valsartan permanently.

scholarly journals Shenlijia Attenuates Doxorubicin-Induced Chronic Heart Failure by Inhibiting Cardiac Fibrosis

2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Xutao Sun ◽  
Yunjia Song ◽  
Ying Xie ◽  
Jieru Han ◽  
Fei Chen ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cardiac Function ◽  
Molecular Mechanisms ◽  
Cardiac Fibrosis ◽  
Heart Function ◽  
Left Ventricular ◽  
Protein Chip ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction

Application of the anticancer drug doxorubicin (DOX) is restricted due to its adverse, cardiotoxic side effects, which ultimately result in heart failure. Moreover, there are a limited number of chemical agents for the clinical prevention of DOX-induced cardiotoxicity. Based on the theories of traditional Chinese medicine (TCM) on chronic heart failure (CHF), Shenlijia (SLJ), a new TCM compound, has been developed to fulfill multiple functions, including improving cardiac function and inhibiting cardiac fibrosis. In the present study, the protective effects and molecular mechanisms of SLJ on DOX-induced CHF rats were investigated. The CHF rat model was induced by intraperitoneal injection of DOX for six weeks with the cumulative dose of 15 mg/kg. All rats were then randomly divided into the control, CHF, CHF + SLJ (3.0 g/kg per day), and CHF + captopril (3.8 mg/kg per day) groups and treated for further four weeks. Echocardiography and the assessment of hemodynamic parameters were performed to evaluate heart function. A protein chip was applied to identify proteins with diagnostic values that were differentially expressed following SLJ treatment. The data from these investigations showed that SLJ treatment significantly improved cardiac function by increasing the left ventricular ejection fraction, improving the hemodynamic index, and inhibiting interstitial fibrosis. Protein chip analysis revealed that SLJ upregulated MCP-1, MDC, neuropilin-2, TGF-β3, thrombospondin, TIE-2, EG-VEGF/PK1, and TIMP-1/2/3 expressions and downregulated that of MMP-13. In addition, immunohistochemistry and western blot results further confirmed that SLJ promoted TIMP-1/2/3 and inhibited MMP-13 expression. The results of the present study suggest that SLJ was effective against DOX-induced CHF rats and is related to the improvement of heart function and ultrastructure and the inhibition of myocardial fibrosis.

scholarly journals Management of Heart Failure Patients with Preserved Left Ventricular Ejection Fraction

2005 ◽  
Vol 6 (2_suppl) ◽  
pp. S15-S16
Author(s):  
Alain Cohen-Solal
Keyword(s):  
Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Ejection Fraction ◽  
Systolic Function ◽  
Left Ventricular ◽  
Ventricular Ejection ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Mortality And Morbidity ◽  
Diagnosis And Management

The diagnosis and management of chronic heart failure (CHF) with preserved left ventricular (LV) systolic function are problematic. Management strategies in current CHF guidelines are largely speculative, as to date few trials have studied such patients.The Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study, the only study that has specifically recruited CHF patients with preserved left ventricular ejection fraction (LVEF), provides direct evidence that treatment with candesartan has substantial clinical benefits in this patient group, and this has been recognised in current guidelines for management of CHF. This treatment strategy warrants consideration in the management of these patients in the routine clinical setting. This case report discusses some of the issues in diagnosis and management of a patient with preserved LVEF.

Efficacy of Vitamin D on Chronic Heart Failure Among Adults

2020 ◽  
Vol 90 (1-2) ◽  
pp. 49-58 ◽  
Author(s):  
Wang Chunbin ◽  
Wang Han ◽  
Cai Lin
Keyword(s):  
Heart Failure ◽  
Vitamin D ◽  
Chronic Heart Failure ◽  
Left Ventricular Ejection Fraction ◽  
Confidence Interval ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Controlled Trials ◽  
Ventricular Ejection Fraction ◽  
Randomized Controlled

Abstract. Vitamin D deficiency commonly occurs in chronic heart failure. Whether additional vitamin D supplementation can be beneficial to adults with chronic heart failure remains unclear. We conducted a meta-analysis to derive a more precise estimation. PubMed, Embase, and Cochrane databases were searched on September 8, 2016. Seven randomized controlled trials that investigated the effects of vitamin D on cardiovascular outcomes in adults with chronic heart failure, and comprised 592 patients, were included in the analysis. Compared to placebo, vitamin D, at doses ranging from 2,000 IU/day to 50,000 IU/week, could not improve left ventricular ejection fraction (Weighted mean difference, WMD = 3.31, 95% confidence interval, CL = −0.93 to 7.55, P < 0.001, I2 = 92.1%); it also exerts no beneficial effects on the 6 minute walk distance (WMD = 18.84, 95% CL = −24.85 to 62.52, P = 0.276, I2 = 22.4%) and natriuretic peptide (Standardized mean difference, SMD = −0.39, 95% confidence interval CL = −0.48 to 0.69, P < 0.001, I2 = 92.4%). However, a dose-response analysis from two studies demonstrated an improved left ventricular ejection fraction with vitamin D at a dose of 4,000 IU/day (WMD = 6.58, 95% confidence interval CL = −4.04 to 9.13, P = 0.134, I2 = 55.4%). The results showed that high dose vitamin D treatment could potentially benefit adults with chronic heart failure, but more randomized controlled trials are required to confirm this result.

Emerging Cardiac Resynchronisation Therapy Indications

2011 ◽  
Vol 7 (1) ◽  
pp. 29
Author(s):  
Charlotte Eitel ◽  
Gerhard Hindricks ◽  
Christopher Piorkowski ◽  
◽  
◽  
...  
Keyword(s):  
Heart Failure ◽  
Systolic Heart Failure ◽  
Cardiac Resynchronisation Therapy ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Current Evidence ◽  
Class Iii ◽  
Ventricular Ejection Fraction ◽  
Cardiac Resynchronisation ◽  
Resynchronisation Therapy

Cardiac resynchronisation therapy (CRT) is an efficacious and cost-effective therapy in patients with highly symptomatic systolic heart failure and delayed ventricular conduction. Current guidelines recommend CRT as a class I indication for patients with sinus rhythm, New York Heart Association (NYHA) functional class III or ambulatory class IV, a QRS duration ≥120ms, and left ventricular ejection fraction (LVEF) ≤35%, despite optimal pharmacological therapy. Recent trials resulted in an extension of current recommendations to patients with mild heart failure, patients with atrial fibrillation, and patients with an indication for permanent right ventricular pacing with the aim of morbidity reduction. The effectiveness of CRT in patients with narrow QRS, patients with end-stage heart failure and cardiogenic shock, and patients with an LVEF >35% still needs to be proved. This article reviews current evidence and clinical applications of CRT in heart failure and provides an outlook on future developments.

Sign in / Sign up

Export Citation Format

Share Document